Identification, Synthesis, and Biological Evaluation of 6-[(6R)-2-(4-Fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H<

详细信息    查看全文

• 作者：Toru Asano ; Hitoshi Yamazaki ; Chiyoshi Kasahara ; Hirokazu Kubota ; Toru Kontani ; Yu Harayama ; Kazuki Ohno ; Hidekazu Mizuhara ; Masaharu Yokomoto ; Keiji Misumi ; Tomohiko Kinoshita ; Mitsuaki Ohta ; Makoto Takeuchi.
• 刊名：Journal of Medicinal Chemistry
• 出版年：2012
• 出版时间：September 13, 2012
• 年：2012
• 卷：55
• 期：17
• 页码：7772-7785
• 全文大小：461K
• 年卷期：v.55,no.17(September 13, 2012)
• ISSN：1520-4804

文摘

Several p38 MAPK inhibitors have been shown to effectively block the production of cytokines such as IL-1尾, TNF伪, and IL-6. Inhibitors of p38 MAP kinase therefore have significant therapeutic potential for the treatment of autoimmune disease. Compound 2a was identified as a potent TNF伪 production inhibitor in vitro but suffered from poor oral bioavailability. Structural modification of 2a led to the discovery of tetrahydropyrazolopyrimidine derivatives, exemplified by compound 3, with an improved pharmacokinetic profile. We found that blocking metabolism at the methyl group of the amine and constructing the tetrahydropyrimidine core were important to obtaining compounds with good biological profiles and oral bioavailability. Pursuing the structure鈥揳ctivity relationships of this series led to the discovery of AS1940477 (3f), with excellent cellular activity and a favorable pharmacokinetic profile. This compound represents a highly potent inhibitor of p38 MAP kinase with regard to in vivo activity in an adjuvant-induced arthritis model.